ARV-471 is an orally administered PROTAC drug targeting the estrogen receptors (ER) in ER+/HER2-locally advanced or metastatic breast cancer patients that is currently undergoing phase I/II clinical trials (NCT04072952). Here, ESR1 is linked to breast carcinoma.